Personalis (PSNL) Stock Price, News & Analysis

Company Overview

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $3.98 to $4.27
• 50-Day Range: $3.00 to $4.49
• 52-Week Range: $1.13 to $7.20
• Volume: 1.19 million shs
• Average Volume: 976,609 shs
• Market Capitalization: $355.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.80
• Consensus Rating: Buy

Personalis Stock Analysis - MarketRank™

Personalis scored higher than 72% of companies evaluated by MarketBeat, and ranked 154th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Personalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Personalis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Personalis is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Personalis is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Personalis has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.51% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Personalis has recently increased by 1.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Personalis does not currently pay a dividend.

Dividend Growth

Personalis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

6.51% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Personalis has recently increased by 1.61%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.56

News Sentiment

Personalis has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Personalis this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Personalis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.80% of the stock of Personalis is held by insiders.

Percentage Held by Institutions

61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PSNL Stock Analysis - Frequently Asked Questions

How have PSNL shares performed this year?

Personalis' stock was trading at $5.78 at the beginning of 2025. Since then, PSNL stock has decreased by 28.3% and is now trading at $4.1440.
View the best growth stocks for 2025 here.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) announced its earnings results on Thursday, February, 27th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. The firm earned $16.80 million during the quarter, compared to analysts' expectations of $15.48 million. Personalis had a negative net margin of 104.52% and a negative trailing twelve-month return on equity of 66.07%.
Read the conference call transcript.

When did Personalis IPO?

Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Personalis' major shareholders?

Personalis' top institutional investors include AIGH Capital Management LLC (4.49%), Sumitomo Mitsui Trust Group Inc. (0.77%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include John Stephen West, Christopher M Hall, Aaron Tachibana, Richard Chen and Stephen Michael Moore.
View institutional ownership trends.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 5/06/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PSNL
• CIK: 1527753
• Web: www.personalis.com
• Phone: (650) 752-1300
• Fax: N/A
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.80
• High Stock Price Target: $9.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +83.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-108,300,000.00
• Net Margins: -104.52%
• Pretax Margin: -104.50%
• Return on Equity: -66.07%
• Return on Assets: -41.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.68
• Quick Ratio: 4.44

Sales & Book Value

• Annual Sales: $84.61 million
• Price / Sales: 4.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.64 per share
• Price / Book: 1.61

Miscellaneous

• Outstanding Shares: 88,308,000
• Free Float: 67,751,000
• Market Cap: $376.19 million
• Optionable: Optionable
• Beta: 1.83